Adamas Pharmaceuticals, Inc.
(NASDAQ : ADMS)

( )
ADMS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
MNKMallinckrodt Plc
-0.28%35.9721.1%$138.29m
PRGOPerrigo Co. Plc
-1.88%74.076.7%$126.06m
SHPGShire PLC Sponsored ADR
0.46%171.430.4%$113.20m
ENDPEndo International Plc
-1.95%15.608.9%$89.97m
JAZZJazz Pharmaceuticals Plc
-0.16%173.972.2%$72.74m
ICPTIntercept Pharmaceuticals, Inc.
3.50%107.0018.7%$69.26m
SAGESAGE Therapeutics, Inc.
3.81%153.879.6%$58.93m
UTHRUnited Therapeutics Corporation
2.46%128.1114.4%$52.33m
CTLTCatalent Inc
0.70%41.582.6%$48.31m
GWPHGW Pharmaceuticals PLC Sponsored ADR
2.41%137.496.8%$42.64m
PTLAPortola Pharmaceuticals, Inc.
1.20%25.327.7%$42.29m
SUPNSupernus Pharmaceuticals, Inc.
-0.11%44.356.2%$40.49m
ICLRICON Plc
1.41%143.944.2%$39.20m
ZGNXZogenix, Inc.
0.86%46.9011.9%$38.19m
HZNPHorizon Pharma plc
-0.63%20.507.4%$33.41m

Company Profile

Adamas Pharmaceuticals, Inc. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products includes ADS-5012, ADS-4101, and Namenda XR. The ADS-5102 is a treatment for levodopa-induced dyskinesia in patients with Parkinson's disease. The ADS-401 treats partial onset seizures in patients with epilepsy. The Namenda XR is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.